<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371017</url>
  </required_header>
  <id_info>
    <org_study_id>MO39193</org_study_id>
    <secondary_id>2016-005119-42</secondary_id>
    <nct_id>NCT03371017</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer</brief_title>
  <acronym>IMpassion132</acronym>
  <official_title>A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared
      with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast
      cancer (TNBC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Anticipated">August 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) in Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
    <description>OS will be tested hierarchically in the following fixed order:
In the population with programmed deathligand 1 (PD-L1)-positive tumour status
In the modified intent-to-treat (mITT) population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) in Modified Intent-To-Treat (mITT) Popluation</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
    <description>OS will be tested hierarchically in the following fixed order:
In the population with programmed deathligand 1 (PD-L1)-positive tumour status
In the modified intent-to-treat (mITT) population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Alive 12 Months</measure>
    <time_frame>Randomization to 12 months post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Alive 18 Months</measure>
    <time_frame>Randomization to 18 months post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status</measure>
    <time_frame>Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 58 months)</time_frame>
    <description>PFS defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause, whichever occurs first.
PFS will be tested hierarchically in the following fixed order:
In the PD-L1-positive population
In the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in mITT population</measure>
    <time_frame>Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 58 months)</time_frame>
    <description>PFS defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause, whichever occurs first.
PFS will be tested hierarchically in the following fixed order:
In the PD-L1-positive population
In the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status</measure>
    <time_frame>Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)</time_frame>
    <description>ORR defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1. ORR will be tested hierarchically in the following fixed order:
In the PD-L1-positive population
In the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Modified Intent-To-Treat (mITT) Popluation</measure>
    <time_frame>Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)</time_frame>
    <description>ORR defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1. ORR will be tested hierarchically in the following fixed order:
In the PD-L1-positive population
In the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DoR)</measure>
    <time_frame>Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 58 months)</time_frame>
    <description>DoR as determined by the investigator according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>8 weeks for the first 12 months after treatment initiation and every 12 weeks thereafter until disease progression (through the end of study, approximately 58 months)</time_frame>
    <description>CBR is defined as the proportion of participants with a CR or a PR or stable disease as determined by the investigator according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response Rate (C-ORR)</measure>
    <time_frame>Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for Confirmed Responders (C-DoR)</measure>
    <time_frame>Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 58 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration (TTD) of GHS/QoL</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
    <description>TTD of GHS/QoL, defined by a minimally important decrease of ≥10 points at two consecutive assessment time-points on the GHS/QoL scale (Items 29, 30) of the EORTC QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Atezolizumab</measure>
    <time_frame>At pre-defined intervals from Day 1, Cycle 1 through Cycle 4 (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Atezolizumab</measure>
    <time_frame>At pre-defined intervals from Day 1, Cycle 1 through Cycle 4 (cycle = 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-Drug Antibodies (ADAs) to Atezolizumab</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between PD-L1 Protein Expression in Screening Tumour Tissue and Clinical Outcomes</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in China Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
    <description>OS will be tested hierarchically in the following fixed order:
In the population with programmed deathligand 1 (PD-L1)-positive tumour status
In the modified intent-to-treat (mITT) population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in mITT China Popluation</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
    <description>OS will be tested hierarchically in the following fixed order:
In the population with programmed deathligand 1 (PD-L1)-positive tumour status
In the modified intent-to-treat (mITT) population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Alive 12 Months in China Population</measure>
    <time_frame>Randomization to 12 months post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Alive 18 Months in China Population</measure>
    <time_frame>Randomization to 18 months post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) in China Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status</measure>
    <time_frame>Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 58 months)</time_frame>
    <description>PFS defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause, whichever occurs first.
PFS will be tested hierarchically in the following fixed order:
In the PD-L1-positive population
In the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) in mITT China Population</measure>
    <time_frame>Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 58 months)</time_frame>
    <description>PFS defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause, whichever occurs first.
PFS will be tested hierarchically in the following fixed order:
In the PD-L1-positive population
In the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in China Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status</measure>
    <time_frame>Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)</time_frame>
    <description>ORR defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1. ORR will be tested hierarchically in the following fixed order:
In the PD-L1-positive population
In the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in Modified Intent-To-Treat (mITT) China Popluation</measure>
    <time_frame>Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)</time_frame>
    <description>ORR defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1. ORR will be tested hierarchically in the following fixed order:
In the PD-L1-positive population
In the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DoR) in China Population</measure>
    <time_frame>Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 58 months)</time_frame>
    <description>DoR as determined by the investigator according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) in China Population</measure>
    <time_frame>8 weeks for the first 12 months after treatment initiation and every 12 weeks thereafter until disease progression (through the end of study, approximately 58 months)</time_frame>
    <description>CBR is defined as the proportion of participants with a CR or a PR or stable disease as determined by the investigator according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response Rate (C-ORR) in China Population</measure>
    <time_frame>Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for Confirmed Responders (C-DoR) in China Population</measure>
    <time_frame>Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 58 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration (TTD) of GHS/QoL in China Population</measure>
    <time_frame>Baseline to end of study (approximately 58 months)</time_frame>
    <description>TTD of GHS/QoL, defined by a minimally important decrease of ≥10 points at two consecutive assessment time-points on the GHS/QoL scale (Items 29, 30) of the EORTC QLQ-C30.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">572</enrollment>
  <condition>Triple Negative Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo on day 1 of each 3-week treatment cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered, 1200 mg by IV infusion with :
gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle</description>
    <arm_group_label>Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered, 1200 mg by IV infusion with :
gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed triple negative breast cancer (TNBC) that is either locally
             recurrent, inoperable and cannot be treated with curative intent or is metastatic

          -  Documented disease progression occurring within 12 months from the last treatment with
             curative intent

          -  Prior treatment (of early breast cancer) with an anthracycline and taxane

          -  Have not received prior chemotherapy or targeted systemic therapy for their locally
             advanced inoperable or metastatic recurrence. Prior radiation therapy for recurrent
             disease is permitted

          -  Measurable or non-measurable disease, as defined by RECIST 1.1

          -  Availability of a representative formalin-fixed paraffin-embedded (FFPE) tumour block
             (preferred) or at least 17 unstained slides, collected within 3 months prior to
             randomisation, with an associated pathology report, if available. If a tumour sample
             taken within 3 months before randomisation is not available and a tumour biopsy is not
             clinically feasible, the primary surgical resection sample or the most recent FFPE
             tumour biopsy sample may be used. Of these additional options, the most recent sample
             should be used.

          -  Eastern Cooperative Oncology Group performance status 0-1

          -  Life expectancy ≥ 12 weeks

          -  Adequate haematologic and end-organ function

          -  Negative human immunodeficiency virus (HIV) test ---Negative hepatitis B surface
             antigen (HBsAg) test at screening

          -  Negative total hepatitis B core antibody (HBcAb) test at screening, or positive HBcAb
             test followed by a negative hepatitis B virus (HBV) DNA test at screening

          -  The HBV DNA test will be performed only for patients who have a negative HBsAg and a
             positive HBcAb test.

          -  Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody
             test followed by a negative HCV RNA test at screening.

          -  Women of childbearing potential must agree to remain abstinent (refrain from
             heterosexual intercourse) or use a contraceptive method with a failure rate of ≤1% per
             year during the treatment period and for at least 5 months after the last dose of
             atezolizumab or 6 months after the last dose of capecitabine, whichever is later. In
             addition, women must refrain from donating eggs during the same time period.

          -  Men must agree to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agree to refrain from donating sperm

        Inclusion criteria for patients enrolled after the recruitment of all-comers is complete:

        -PD-L1-positive tumour status (assessed centrally prior to randomisation), defined as PD-L1
        expression on tumour-infiltrating immune cells (IC) of 1% or greater.

        Exclusion Criteria:

          -  Spinal cord compression not definitively treated with surgery and/or radiation, or
             previously diagnosed and treated spinal cord compression without evidence that disease
             has been clinically stable for &gt; 2 weeks prior to randomisation

          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases.

          -  Symptomatic or rapid visceral progression

          -  No prior treatment with an anthracycline and taxane

          -  History of leptomeningeal disease

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures (once monthly or more frequently) (patients with indwelling
             catheters such as PleurX® are allowed)

          -  Uncontrolled tumour-related pain

          -  Uncontrolled or symptomatic hypercalcemia

          -  Malignancies other than TNBC within 5 years prior to randomisation)

          -  Significant cardiovascular disease, within 3 months prior to randomisation, unstable
             arrhythmias, or unstable angina

          -  Presence of an abnormal ECG

          -  Severe infection requiring oral or IV antibiotics within 4 weeks prior to
             randomisation, including but not limited to hospitalization for complications of
             infection, bacteraemia, or severe pneumonia.

          -  Current treatment with anti-viral therapy for HBV.

          -  Major surgical procedure within 4 weeks prior to randomisation or anticipation of the
             need for a major surgical procedure during the course of the study other than for
             diagnosis

          -  Treatment with investigational therapy within 28 days prior to randomisation

          -  Pregnant or lactating, or intending to become pregnant during or within 5 months after
             the last dose of atezolizumab, or within 6 months after the last dose of capecitabine,
             whichever is later.

        Exclusion Criteria Related to Atezolizumab:

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanised antibodies or fusion proteins

          -  Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster
             ovary cells or to any component of the atezolizumab formulation

          -  History of autoimmune disease

          -  Prior allogeneic stem cell or solid organ transplantation

          -  History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
             pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic
             organizing pneumonia), or evidence of active pneumonitis on screening chest
             computerised tomography (CT) scan History of radiation pneumonitis in the radiation
             field (fibrosis) is permitted.

          -  Active tuberculosis

          -  Receipt of a live, attenuated vaccine within 4 weeks prior to randomisation or
             anticipation that a live, attenuated vaccine will be required during
             atezolizumab/placebo treatment or within 5 months after the last dose of
             atezolizumab/placebo

          -  Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or
             pathway targeting agents

          -  Treatment with systemic immunostimulatory agents (including but not limited to
             interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug
             (whichever is longer) prior to randomisation

          -  Treatment with systemic corticosteroids or other systemic immunosuppressive
             medications within 2 weeks prior to randomisation, or anticipated requirement for
             systemic immunosuppressive medications during the trial

        Exclusion Criteria Related to Capecitabine:

          -  Inability to swallow pills

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function,
             resection of the stomach or small bowel, or ulcerative colitis

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency or history of severe and
             unexpected reactions to fluoropyrimidine therapy in patients selected to receive
             capecitabine

        Exclusion Criteria Related to Carboplatin/Gemcitabine:

        -Hypersensitivity to platinum containing compounds or any component of carboplatin or
        gemcitabine drug formulations in patients selected to receive carboplatin and Gemcitabine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: MO39193 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Cancer Specialists - Fort Myers (Broadway)</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers PC - Marietta</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Division</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Magee-Woman's Hospital; UPMC Pinnacle Cancer Center</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Magee-Woman's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology; Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalo-univerisitaire de Rouiba;Service d'oncologie médicale</name>
      <address>
        <city>Algiers</city>
        <zip>16016</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Anti Cancer Beau-fraisier;Service d'oncologie médicale</name>
      <address>
        <city>Algiers</city>
        <zip>16340</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Constantine; Service d'Oncologie Médicale</name>
      <address>
        <city>Constantine</city>
        <zip>25000</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fundación CENIT para la Investigación en Neurociencias</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1125ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Metabolicas (Idim)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial del Centenario</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncología de Rosario</name>
      <address>
        <city>Rosario</city>
        <zip>S2000KZE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of the Republic of Srpska</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic of Oncology, University Clinical Center Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>7100</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Araujo Jorge; Departamento de Ginecologia E Mama</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74605-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital do Cancer de Pernambuco - HCP</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <zip>50040-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <zip>99010-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Perola Byington</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01317-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Anhui</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital , Chinese Academy of Medical</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha City</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Yet-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital Zhejiang University</name>
      <address>
        <city>Hangzhou City</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Jinzhou Medical University</name>
      <address>
        <city>Jinzhou City</city>
        <zip>121001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Medical College Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai City</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center; Medical Oncology</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liaoning cancer Hospital &amp; Institute</name>
      <address>
        <city>Shenyang</city>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Zhejiang</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Hermanos Ameijeiras</name>
      <address>
        <city>La Habana</city>
        <zip>10300</zip>
        <country>Cuba</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Oncología y Radiología (INOR)</name>
      <address>
        <city>La Habana</city>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ain Shams University Hospital; Oncology</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>AirForce Specialized Hospital; Clinical Oncology</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital; Dept of Oncology</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital; Dept of Oncology</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turku Uni Central Hospital; Oncology Clinics</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Lecler; Ctr de Lutte Contre le Canc</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard; Oncologie Genetique</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes; Oncologie Medicale 1</name>
      <address>
        <city>Marseille Cedex 09</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>INSTITUT CURIE_SITE PARIS - Service d'Oncologie Médicale.</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis; Service d'oncologie</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin; Oncologie Medicale</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>IGR</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare)</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot;; Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst GmbH; Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH Krankenhaus Holweide; Brustzentrum</name>
      <address>
        <city>Köln</city>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Prof. Dr.med. Christoph Salat und Dr.med. Oliver J. Stötzer</name>
      <address>
        <city>München</city>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Caritas-Krankenhaus St. Josef; Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Szent Margit Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz;Sugarterapias Klinikai Onkologiai Intez</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem; Klinikai Központ Onkoterápiás Intézet</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l.</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico</name>
      <address>
        <city>Candiolo</city>
        <state>Piemonte</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Antonio Perrino; Oncologia Medica</name>
      <address>
        <city>Brindisi</city>
        <state>Puglia</state>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department</name>
      <address>
        <city>Almaty</city>
        <zip>050022</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Almaty Cancer Hospital; Chemotherapy department</name>
      <address>
        <city>Almaty</city>
        <zip>050054</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multidisciplinary medical center; Chemotherapy department</name>
      <address>
        <city>Astana</city>
        <zip>010000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13605</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Dalinde</name>
      <address>
        <city>Cdmx</city>
        <state>Mexico CITY (federal District)</state>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia; Oncology</name>
      <address>
        <city>Distrito Federal</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consultorio de Medicina Especializada; Dentro de Condominio San Francisco</name>
      <address>
        <city>Mexico City</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Montenegro; Clinic for Oncology and Radiotherapy</name>
      <address>
        <city>Podgorica</city>
        <zip>81000</zip>
        <country>Montenegro</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Mohamed VI; Oncologie-Hématologie</name>
      <address>
        <city>Marrakech</city>
        <zip>40000</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique specialise Menara; Oncology Medical</name>
      <address>
        <city>Marrakech</city>
        <zip>40000</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut National D'oncologie Sidi Med Benabdellah</name>
      <address>
        <city>Rabat</city>
        <zip>6213</zip>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hemato Oncologico Panama</name>
      <address>
        <city>Panama</city>
        <zip>0832</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Świętokrzyskie Centrum Onkologii; Dział Chemioterapii</name>
      <address>
        <city>Kielce</city>
        <zip>25-734</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Oncologia Medica</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Porto - Hospital de Santo António; Oncologia</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPO do Porto; Servico de Oncologia Medica</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moscow City Oncology Hospital #62</name>
      <address>
        <city>Moscovskaya Oblast</city>
        <state>Moskovskaja Oblast</state>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moscow Clinical Scientific Center</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;National Medical Research Center of Oncology N.N. Blokhin&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Dispensary, SPb SBIH CCOD</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>FBI &quot;Scientific Research Institute of Oncology n. a. N. N. Petrov&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Bezanijska kosa; Clinic for Oncology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology and Radiology of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis, Clinic for Oncology</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Hospital; National University Cancer Institute, Singapore (NCIS)</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre; Medical Oncology</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cape Town Oncology Trials</name>
      <address>
        <city>Cape Town</city>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Oncology centre,Durban; Clinical Oncology</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Centre of Rosebank; Oncology</name>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Richards Bay Oncology Centre</name>
      <address>
        <city>KwaZulu Natal</city>
        <zip>3900</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pretoria Oncology Department; Medical Oncology</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Private Oncology Centre</name>
      <address>
        <city>Pretoria</city>
        <zip>0081</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces; Servicio de Oncologia</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia; Servicio de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty; Department of Internal Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara Oncology Hospital; Medical Oncology Department</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty; Medical Oncology Department</name>
      <address>
        <city>Bornova, İ̇zmi̇r</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medipol University MF; Oncology Department</name>
      <address>
        <city>Istanbul</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marmara University Pendik Training and Research Hospital; Medikal Onkoloji</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Necmettin Erbakan University Meram Medical Faculty ; Internal Diseases</name>
      <address>
        <city>Konya</city>
        <zip>42080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre; Oncology Dept</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital; Edinburgh Cancer Center</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts</name>
      <address>
        <city>London</city>
        <zip>EC1M6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas NHS Foundation Trust, Guys Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke on Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Argentina</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Cuba</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Kazakhstan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Montenegro</country>
    <country>Morocco</country>
    <country>Panama</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

